Surrozen, Inc. (NASDAQ:SRZN) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Surrozen, Inc. (NASDAQ:SRZN) has been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $61.75.

Several equities research analysts have recently issued reports on SRZN shares. William Blair assumed coverage on Surrozen in a research note on Thursday, August 20th. They issued an “outperform” rating and a $51.00 price objective for the company. Cantor Fitzgerald increased their target price on shares of Surrozen from $40.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday. Guggenheim set a $80.00 price objective on shares of Surrozen and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $54.00 target price (up from $44.00) on shares of Surrozen in a research note on Friday, September 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, October 15th.

Surrozen Price Performance

Shares of Surrozen stock opened at $31.88 on Friday. Surrozen has a 12 month low of $12.12 and a 12 month high of $37.83. The stock has a 50 day moving average of $25.54 and a 200 day moving average of $25.42.

Surrozen (NASDAQ:SRZN) last posted its earnings results on Monday, November 9th. The company reported ($11.02) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($9.92). As a group, analysts forecast that Surrozen will post -1.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Surrozen

Several large investors have recently added to or reduced their stakes in SRZN. Global Retirement Partners LLC purchased a new position in Surrozen during the 3rd quarter worth $45,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Surrozen by 37.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,000 shares of the company’s stock worth $160,000 after purchasing an additional 1,350 shares during the period. Bank of New York Mellon Corp purchased a new position in Surrozen during the second quarter valued at approximately $399,000. Perceptive Advisors LLC bought a new position in Surrozen in the first quarter worth approximately $6,682,000. Finally, ADAR1 Capital Management LLC bought a new stake in Surrozen during the 1st quarter valued at $350,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Surrozen Company Profile

Surrozen, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation. The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.